Administration of CSP at a dose of 12 mg/kg every other day did not add benefit when given with prednisone for treatment of newly diagnosed chronic GVHD.

(A) Mortality from causes other than recurrent malignancy, where recurrent malignancy is considered a competing risk (P = .11). (B) Survival without recurrent malignancy (P = .03). (C) Secondary therapy for chronic GVHD, where recurrent malignancy is considered a competing risk (P = .35). Tic marks indicate censors at date of last contact, and numbers at the end of each curve indicate point estimates at the end of follow-up.